Phone No.
(780) 450-3957
Mycotoxin testing helps natural health product manufacturers, supplement companies, ingredient suppliers and quality teams evaluate contamination risks associated with botanical, agricultural and other plant-derived materials.
Depending on the product and ingredient profile, testing may include:
PBR Laboratories provides mycotoxin testing support from Edmonton for applicable natural health products, supplements and related ingredients across Alberta, Western Canada and Canada.
The key question is not simply whether a mycotoxin is detected. It is:
Does the measured result meet the applicable specification, and what supplier, ingredient or finished-product decision should follow?
PBR's service catalogue documents aflatoxin and ochratoxin A testing capabilities for applicable plant, oil and edible matrices.
Mycotoxins are toxic compounds produced by certain moulds that can affect agricultural, botanical and plant-derived materials.
For natural health products, mycotoxin risk can be influenced by:
Not every natural health product presents the same risk.
A botanical powder, grain-derived ingredient or plant material may have very different contamination considerations from a highly refined ingredient.
That is why testing should be based on the ingredient, matrix, supplier risk and product specification.
PBR's documented capabilities include:
Aflatoxin B1 testing can support evaluation of applicable botanical, agricultural or plant-derived ingredients where aflatoxin contamination is a concern.
Aflatoxin B2 may be included as part of an aflatoxin testing panel for relevant materials.
Aflatoxin G1 can contribute to total aflatoxin assessment in applicable matrices.
Aflatoxin G2 may also form part of a broader aflatoxin testing panel.
Total aflatoxin testing combines the relevant aflatoxin components to support comparison with an established specification or acceptance criterion.
PBR's service catalogue also documents Ochratoxin A testing for applicable plant, oil and edible matrices.
Mycotoxin testing may be appropriate when the ingredient or product contains materials with a relevant contamination risk.
Testing can support:
Mycotoxins may not be evenly distributed through a lot.
A contaminated portion of botanical powder, grain-derived material or another heterogeneous ingredient may contain a higher concentration than another portion from the same shipment.
That means a laboratory result can only be as representative as the sample submitted.
PBR's decision framework specifically notes that mycotoxins may be unevenly distributed and that sampling design strongly affects confidence in the result.
Common sampling problems include:
Composite sampling can reduce analytical cost and provide an average representation of a lot.
However, it can also dilute localized contamination.
A contaminated increment may be combined with multiple low-result increments, producing an average that does not clearly identify the localized problem.
PBR's framework specifically warns that compositing can dilute localized contamination and recommends defining lot coverage, retained units and follow-up testing before the sampling plan is finalized.
Ask PBR about sampling before submitting a large or heterogeneous lot.
Raw materials are often the most important point for mycotoxin risk assessment.
Testing botanical and plant-derived ingredients before manufacturing may support:
Before submitting the sample, establish:
Related Service: Ingredient & Raw Material Testing →
Finished-product testing may also be relevant depending on the ingredients and product specification.
It can support:
A finished-product result should be interpreted in the context of the formulation and the ingredients contributing to the potential mycotoxin risk.
Related Service: Finished Product Testing →
A laboratory result reports the concentration measured in the submitted sample.
The result should be compared with:
A detected mycotoxin does not automatically tell the quality team whether the product passes or fails.
The correct interpretation is:
Measured concentration → Applicable specification → Quality review → Accept, investigate or take corrective action
An above-specification result should be reviewed in context.
The investigation may need to consider:
Not automatically.
If contamination is unevenly distributed, repeating a test on another small sample may give a different result without resolving the underlying question.
The investigation should first determine what additional sampling or testing would meaningfully support the quality decision.
That follows PBR's core decision-first standard: testing should answer a defined question rather than simply generate another result.
Mycotoxin risk and mould growth are separate but related quality considerations.
Moisture conditions can influence fungal growth during ingredient storage, while mycotoxin contamination may reflect earlier growing, processing or storage conditions.
Testing may therefore involve more than one analytical parameter depending on the investigation.
Relevant related testing can include:
A moisture or yeast-and-mould result does not replace specific mycotoxin analysis where the decision requires aflatoxin or ochratoxin information.
Related Service: Stability & Quality Testing →
What is the difference between mycotoxin testing and yeast and mould testing?
Yeast and mould testing measures viable fungal populations under the applicable microbiological method.
Mycotoxin testing measures specific toxic compounds produced by certain moulds.
The presence or absence of viable mould at the time of testing does not automatically establish whether mycotoxins are present.
These tests answer different questions.
Related Service: Natural Health Product Microbiology Testing →
Botanical ingredients can have higher mycotoxin relevance because contamination risk may be influenced by growing, harvesting, drying and storage conditions.
Powders containing botanical or agricultural ingredients may require mycotoxin testing depending on source materials and specifications.
Products containing plant-derived proteins, grains or other agricultural ingredients may require mycotoxin consideration depending on formulation and supplier risk.
Capsules or tablets containing botanical ingredients may require mycotoxin testing based on ingredient risk and the finished-product specification.
The need for mycotoxin testing depends on the ingredients used in the liquid formulation rather than the dosage form alone.
Mycotoxin testing is generally driven by ingredient risk rather than the product category itself. Products containing botanical or agricultural components may require additional consideration.
PBR Laboratories provides mycotoxin testing support from Edmonton for applicable natural health products, supplements and ingredients.
PBR gives Alberta manufacturers, suppliers and quality teams regional access to laboratory support and direct discussion of ingredient matrices, sampling and testing objectives.
PBR supports natural health product and supplement businesses throughout Western Canada with mycotoxin testing selected around the material, specification and quality decision.
PBR supports Canadian clients requiring applicable aflatoxin and Ochratoxin A testing for natural health products, supplements and plant-derived ingredients.
The objective is not simply to report a mycotoxin concentration.
PBR helps clients understand how the result relates to the sampled lot, applicable specification and the next supplier or quality decision.
PBR's documented capabilities include Aflatoxin B1, B2, G1, G2, total aflatoxins and Ochratoxin A for applicable matrices.
Testing may be appropriate where the botanical or agricultural ingredient has a relevant contamination risk based on its source, storage history, supplier controls or product specification.
No. Yeast and mould testing measures viable fungal populations, while mycotoxin testing measures specific toxic compounds associated with certain moulds. One test does not replace the other.
Mycotoxins can be unevenly distributed through heterogeneous materials. A small non-representative sample may therefore provide limited information about a large lot. Representative lot sampling is critical when results will support an acceptance or rejection decision.
Compositing may provide an average result across multiple increments, but it can also dilute localized contamination. The sampling design should be based on lot coverage and the decision the result must support.
That depends on the product, ingredients and specification. Ingredient testing can help control risk before manufacturing, while finished-product testing may support final quality assessment.
Review sample representativeness, supplier and lot information, storage conditions and related analytical results before deciding on follow-up sampling or testing.
Yes. PBR provides testing support from Edmonton for clients throughout Alberta, Western Canada and Canada.
Tell PBR:
PBR can discuss available aflatoxin and Ochratoxin A testing, matrix considerations and sample requirements.